Brown’s Giuliani RNA Center and the Rhode Island Life Science Hub co-hosted a symposium focused on how scientists can work ...
That’s now happening. Researchers have uncovered genes that play a role in a number of chronic conditions. And they have invented new types of therapies to target their genetic roots. One of the most ...
Corn rootworms, pests responsible for billions of dollars in yearly crop losses, are evolving resistance that weakens even ...
A Vancouver agri-tech company wants to give canola growers another weapon in the never-ending battle against flea beetles.
According to DataM Intelligence, "The RNA-Based Therapies Market Size, valued at USD 90.56 billion in 2024, is projected to ...
EPA registration paves the way for beekeepers to combat a critical threat to pollinator health BOSTON, Sept. 25, 2025 /PRNewswire/ -- GreenLight ...
(Reuters) -Swiss drugmaker Novartis has signed an up to $5.2 billion licensing and options deal with Argo Biopharmaceutical for its experimental candidates that target cardiovascular diseases, the ...
Ionis is a leader in RNA-based therapies. Its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The firm's antisense ...
According to DataM Intelligence, "The RNA-Based Therapies Market Size, valued at USD 90.56 billion in 2024, is projected to reach USD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback